Search

Joseph A Madri

from Guilford, CT
Age ~78
Get Report
Also known as:
Joseph Dr Madri, Joseph Mandri, Lucille Madri
Phone and address:
57 Landons Way, Guilford, CT 06437
(860) 618-0379
Related to:
Allison J Leckel, 42Jessica Haglund, 47Betty M Haglund, 89Kurt Haglund, 65Erick Haglund, 89Elva Haglund
Connected to:
Aida Madriaga, 108Angela C Madriaga, 35Baldwin R Madriaga, 55Daniel J Madriaga, 42Danilo E Madriaga, 58Franc Madriaga, 31Froilan C Madriaga, 58Joanne Madriaga, 78Michael N Madriaga, 39Neomi Madriaga, 36

Joseph Madri Phones & Addresses

  • 57 Landons Way, Guilford, CT 06437 (860) 618-0379
  • 221 Pond Rd, North Branford, CT 06471 (203) 481-2220
  • 221 Pond Road Ext, North Branford, CT 06471 (203) 481-2220
  • New Haven, CT
  • Goshen, CT

Work

Company: YALE U Address: 310 Cedar St, New Haven, CT 06510 Phones: (203) 432-3775 (203) 785-7303

Education

School / High School: Indiana University / School of Medicine 1975

Languages

English

Awards

Healthgrades Honor Roll

Ranks

Certificate: Anatomic Pathology, 1979

Emails

j***[email protected]

Specialities

Anatomic Pathology

Professional Records

Medicine Doctors

Joseph Madri Photo 1

Dr. Joseph A Madri, New Haven CT - MD (Doctor of Medicine)

View page
Specialties:
Anatomic Pathology
Address:
YALE U
310 Cedar St, New Haven, CT 06510
(203) 432-3775 (Phone), (203) 785-7303 (Fax)
Certifications:
Anatomic Pathology, 1979
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Indiana University / School of Medicine
Graduated: 1975
Medical School
Yale Med Ctr
Graduated: 1975
Joseph Madri Photo 2

Joseph Anthony Madri, New Haven CT

View page
Specialties:
Pathology
Anatomic Pathology
Work:
Yale University
310 Cedar St, New Haven, CT 06510
Education:
Indiana University(1975)

Publications

Us Patents

Universal Donor Cells

View page
US Patent:
6916654, Jul 12, 2005
Filed:
May 5, 2000
Appl. No.:
09/566254
Inventors:
Peter J. Sims - Mequon WI, US
Alfred L. M. Bothwell - Guilford CT, US
Eileen A. Elliot - New Haven CT, US
Richard A. Flavell - Killingworth CT, US
Joseph Madri - North Branford CT, US
Scott Rollins - Monroe CT, US
Leonard Bell - Woodbridge CT, US
Stephen Squinto - Irvington NY, US
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
Yale University - New Haven CT
International Classification:
C12N005/10
C12N015/63
A61K048/00
A01N067/027
US Classification:
435325, 4353201, 435455, 800 8, 800 13, 800 18, 514 44
Abstract:
Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i. e. , hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.

Early Diagnosis Of Congenital Abnormalities In The Offspring Of Diabetic Mothers

View page
US Patent:
20090305259, Dec 10, 2009
Filed:
Mar 21, 2007
Appl. No.:
12/281767
Inventors:
Joseph Madri - North Branford CT, US
Anjali Nath - Guilford CT, US
Michael Krauthammer - New Haven CT, US
Michael Snyder - Fairfield CT, US
Eugene Davidov - Hamden CT, US
Assignee:
YALE UNIVERSITY - New Haven CT
International Classification:
C12Q 1/68
G01N 33/53
G01N 33/00
C12Q 1/54
C12Q 1/37
C12Q 1/02
US Classification:
435 6, 435 71, 435 792, 435 14, 435 23, 435 29
Abstract:
The present invention relates to the identification of a series of biomarkers, the detection of which is prognostic for women at risk of becoming hyperglycemic during pregnancy and/or fetuses at risk of developing congenital anomalies as a result of maternal hyperglycemia.

Genetically Engineered Endothelial Cells Exhibiting Enhanced Migration And Plasminogen Activator Activity

View page
US Patent:
53366158, Aug 9, 1994
Filed:
Jan 6, 1992
Appl. No.:
7/820011
Inventors:
Leonard Bell - Woodbridge CT
Joseph A. Madri - North Branford CT
Stephen L. Warren - Orange CT
Daniel J. Luthringer - Beverly Hills CA
Assignee:
Yale University - New Haven CT
International Classification:
C12N 510
C12N 506
C12N 1585
A61F 206
US Classification:
4352402
Abstract:
Genetically engineered endothelial cells which exhibit enhanced cell migration and enhanced urokinase-type plasminogen activator (u-PA) activity are provided. The cells are modified by incorporation of the coding sequence for the c-src gene so that the cells express elevated levels of the tyrosine kinase protein, pp60. sup. c-src. The C-src gene is a naturally occurring gene which appears to be present in all animal species and is highly conserved. Because of their enhanced migration rates, the modified cells can be used to efficiently seed denuded segments of vessels or natural or synthetic grafts prior to implantation. Because of their enhanced u-PA activity, the cells can reduce the probability of thrombus formation at sites of vessel damage, such as that produced during such surgical procedures as coronary angioplasty and vessel reconstruction with grafts, stents, or the like.

Universal Donor Cells

View page
US Patent:
6100443, Aug 8, 2000
Filed:
Jun 7, 1995
Appl. No.:
8/483433
Inventors:
Peter J. Sims - Mequon WI
Alfred L. M. Bothwell - Guilford CT
Eileen A. Elliot - New Haven CT
Richard A. Flavell - Killingworth CT
Joseph Madri - North Branford CT
Scott Rollins - Monroe CT
Leonard Bell - Woodbridge CT
Stephen Squinto - Irvington NY
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
Yale University - New Haven CT
International Classification:
C12N 1585
A01K 6700
A61K 4800
A61F 206
US Classification:
800 14
Abstract:
Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i. e. , hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.

Universal Donor Cells

View page
US Patent:
57057320, Jan 6, 1998
Filed:
Jul 1, 1993
Appl. No.:
8/087007
Inventors:
Peter J. Sims - Mequon WI
Alfred L.M. Bothwell - Guilford CT
Eileen A. Elliot - New Haven CT
Richard A. Flavell - Killingworth CT
Joseph Madri - North Branford CT
Scott Rollins - Monroe CT
Leonard Bell - Woodbridge CT
Stephen Squinto - Irvington NY
Assignee:
Oklahoma Medical Research Foundation - Oklahoma City OK
Yale University - New Haven CT
International Classification:
C12N 1500
C07H 2102
US Classification:
800 2
Abstract:
Genetically engineered cells are provided which can serve as universal donor cells in such applications as reconstruction of vascular linings or the administration of therapeutic agents. The cells include a coding region which provides protection against complement-based lysis, i. e. , hyperacute rejection. In addition, the cell's natural genome is changed so that functional proteins encoded by either the class II or both the class I and the class II major histocompatibility complex genes do not appear on the cell's surface. In this way, attack by T-cells is avoided. Optionally, the cells can include a self-destruction mechanism so that they can be removed from the host when no longer needed.

Innate Immune System Modification For Anticancer Therapy

View page
US Patent:
20170218036, Aug 3, 2017
Filed:
Sep 29, 2015
Appl. No.:
15/515075
Inventors:
- New Haven CT, US
Michael SNYDER - Stanford CA, US
Joseph A. MADRI - North Branford CT, US
International Classification:
C07K 14/47
C12Q 1/68
A61K 39/00
Abstract:
The present invention relates to the discovery of a role of the nuclear receptor retinoid-related orphan receptor gamma (RORgamma) in tumor suppression. The introduction and expression of RORgamma result in genes activation within innate immune cells that trigger recognition and suppression of tumor cells. Thus, in various embodiments described herein, the invention encompasses a composition or a cell comprising a viral vector comprising nucleic acid sequences encoding RORgamma under the control of a neutrophil specific promoter. Additionally, the invention relates to methods of treating cancer by administering to a subject a composition that confers or increases innate immune cell anti-tumor immunity, methods for providing anti-tumor immunity in a subject, methods of stimulating innate immune response to a cell population or a tissue in a mammal and methods of diagnosing anti-tumor immunity response. Furthermore, the invention encompasses a kit for carrying out the aforementioned methods.
Control profile
Joseph A Madri from Guilford, CT, age ~78 Get Report